Genmab’s $8B Merus Deal Fuels Growth as Stock Eyes Cup-Base Entry
Genmab announced an $8B deal to acquire Merus, strengthening its ADC capabilities. Shares trade just under an early cup‑base entry after being named IBD's Stock of the Day.
Investor's Business Daily
2 min read
Stocks
Market Analysis
Biotechnology